Lower risk threshold, potentially broader benefit
Routine liver cancer surveillance could be worthwhile for more people with alcohol-associated cirrhosis than current screening thresholds indicate, according to a study led by investigators at Mass General Brigham.
The analysis, published in Clinical Gastroenterology and Hepatology, concluded that screening every six months was beneficial and cost-effective for people whose annual risk of hepatocellular carcinoma, the most common form of liver cancer, was as low as 0.45%.
That figure is well below the 1% annual-risk benchmark that has commonly guided decisions on whether to offer regular surveillance. The difference matters because alcohol-associated cirrhosis raises liver cancer risk, but many patients fall below the existing cutoff.
The authors say the evidence could support a reassessment of which patients are offered regular checks, with the goal of detecting cancers at stages when treatment options may be more effective.
Why alcohol-associated cirrhosis creates a screening dilemma
Alcohol-associated cirrhosis is an advanced stage of liver disease in which scarring replaces healthy liver tissue and compromises normal liver function. It is associated with heavy drinking and significantly increases the likelihood of hepatocellular carcinoma.
Surveillance is not a trivial intervention. Regular screening requires an ultrasound examination and a blood test, creating costs, appointments and follow-up demands for patients and health systems. That is why eligibility thresholds have played an important role in clinical guidance.
But the 1% annual-risk threshold was based on older evidence drawn largely from people with viral hepatitis. More recent data indicate that annual liver cancer risk among people with alcohol-associated cirrhosis is often below that level. The result has been an important uncertainty: patients may face meaningful risk while still not qualifying for routine surveillance under a threshold developed for a different population.
The new study addresses that gap by examining whether present-day screening and treatment pathways change the economic and clinical case for surveillance.
Twice-yearly surveillance showed value at 0.45% risk
The investigators found that biannual surveillance remained cost-effective and life-extending at an annual hepatocellular carcinoma risk of 0.45%. In practical terms, the finding suggests that waiting for a patient to reach the traditional 1% benchmark may exclude people for whom screening could still provide good value and improve the chance of earlier diagnosis.
Earlier detection is central to the rationale for surveillance. Liver cancers identified at a more treatable stage can give clinicians and patients more options than cancers found after symptoms develop. The study does not establish that every person with alcohol-associated cirrhosis should receive identical care, but it challenges the assumption that risks below 1% are automatically too low to justify a routine program.
Senior author Jagpreet Chhatwal, director of the Center for Health Technology Assessment at Mass General Brigham and an associate professor of radiology at Harvard Medical School, said the longstanding benchmark is outdated for this population. He said contemporary testing and treatments provide value at lower risk levels and that the evidence base for screening eligibility should be updated.
Finding applies to patients who drink and those who stop
The reported benefit extended to people who continued to drink and to those who had achieved abstinence. That distinction is consequential: abstinence is an important health goal, but it does not erase the effects of established cirrhosis or remove the need to consider cancer risk.
For clinicians, the study reinforces the need to separate two related questions. One is how to support alcohol reduction or abstinence. The other is how to monitor a patient who already has advanced liver disease. The study argues that surveillance can remain valuable across those circumstances when cancer risk reaches a lower threshold than current guidance has generally used.
What could change next
The findings are evidence for guideline discussions rather than a replacement for individualized clinical judgment. Screening decisions still depend on a patient’s liver disease, overall health, ability to undergo follow-up and potential treatment if cancer is found.
Still, the work adds pressure to reconsider an eligibility rule that was derived primarily from another disease group. If professional guidance eventually adopts a lower threshold for alcohol-associated cirrhosis, more patients could become candidates for ultrasound-and-blood-test surveillance every six months.
The central message is straightforward: lower annual cancer risk does not necessarily mean surveillance lacks value. For a population with alcohol-associated cirrhosis, the study suggests that modern screening and treatment options may justify looking earlier and more consistently for liver cancer.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
